A2A Pharma Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Employees
  • 9

Employees
  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $6.5M

  • Investors
  • 3

A2A Pharma General Information

Description

Developer of a therapeutic design platform designed to accelerate the development of novel drug alternatives for life-threatening diseases. The company's platform is useful to treat antibiotic-resistant bacterial infections and cancer and bacterial infections including Tuberculosis through its proprietary computational system, enabling healthcare professionals and physicians to treat their patients in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Pharmaceuticals
Primary Office
  • BioLabs New York
  • 180 Varick Street
  • New York, NY 10014
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

A2A Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 06-Feb-2018 $6.5M 00.00 Completed Generating Revenue
3. Accelerator/Incubator 12-Dec-2017 00000 Completed Generating Revenue
2. Accelerator/Incubator 02-Nov-2016 $200K $200K 00.00 Completed Generating Revenue
1. Seed Round 01-Apr-2016 Completed Generating Revenue
To view A2A Pharma’s complete valuation and funding history, request access »

A2A Pharma Patents

A2A Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4058447-A1 Isoxazole derivatives targeting tacc3 as anticancer agents Pending 14-Nov-2019 0000000000
US-20210220369-A1 Highly potent tacc3 inhibitor as a novel anticancer drug candidate Pending 25-May-2018 0000000000 0
EP-3801529-A2 Highly potent tacc3 inhibitor as a novel anticancer drug candidate Pending 25-May-2018 00000000000
EP-3801529-A4 Highly potent tacc3 inhibitor as a novel anticancer drug candidate Pending 25-May-2018 00000000000 0
US-20210068876-A1 Proximal femoral de-rotation nail Pending 04-Apr-2018 A61B17/7241 0
To view A2A Pharma’s complete patent history, request access »

A2A Pharma Executive Team (7)

Name Title Board Seat Contact Info
Sotirios Stergiopoulos MD Co-Founder, President and Chief Executive Officer
Sridhar Vempati Ph.D Co-Founder, Chief Strategy Officer & Executive Vice President of R&D
Edward Painter Co-Founder, Chief Information Officer and Chairman
Chaemin Lim Ph.D Chief Scientific Officer
You’re viewing 4 of 7 executive team members. Get the full list »

A2A Pharma Board Members (3)

Name Representing Role Since
Andrew Dean Ph.D A2A Pharma Board Member 000 0000
Edward Painter A2A Pharma Co-Founder, Chief Information Officer and Chairman 000 0000
You’re viewing 2 of 3 board members. Get the full list »

A2A Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

A2A Pharma Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Johnson & Johnson Innovation - JLABS Accelerator/Incubator Minority 000 0000 000000 0
IndieBio Accelerator/Incubator Minority 000 0000 000000 0
SOSV Venture Capital Minority 000 0000 000000 0
To view A2A Pharma’s complete investors history, request access »

A2A Pharma Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000.00 19-Jul-2018 00000 0000 Other Healthcare Technology Systems 00000 000
To view A2A Pharma’s complete investments history, request access »